Key clinical point: Ivosidenib may be effective against nonenhancing IDH1-mutated advanced glioma.
Major finding: The median progression-free survival was 13.6 months for patients with nonenhancing tumors and 1.4 months for patients with enhancing tumors.
Study details: A phase 1 study of 66 adults with IDH1-mutated advanced gliomas.
Disclosures: The research was funded by Agios Pharmaceuticals, the company developing ivosidenib. The researchers disclosed relationships, including employment, with the company.
Mellinghoff I et al. J Clin Oncol. 2020 Jun 12. doi: 10.1200/JCO.19.03327